varenicline (CP-526,555)

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Smoking Cessation

Conditions

Smoking Cessation

Trial Timeline

Jan 1, 2005 → Jun 1, 2006

NCT ID

NCT00143325

About varenicline (CP-526,555)

varenicline (CP-526,555) is a phase 3 stage product being developed by Pfizer for Smoking Cessation. The current trial status is completed. This product is registered under clinical trial identifier NCT00143325. Target conditions include Smoking Cessation.

What happened to similar drugs?

17 of 20 similar drugs in Smoking Cessation were approved

Approved (17) Terminated (0) Active (3)

✅Nicotine patch, nicotine inhaler, bupropion + Nicotine patchJohnson & JohnsonApproved

✅varenicline + placeboPfizerApproved

✅placebo + vareniclinePfizerApproved

✅Varenicline + PlaceboPfizerApproved

✅varenicline + vareniclinePfizerApproved

✅Varenicline Tartrate + PlaceboPfizerApproved

✅placebo + varenicline tartrate + bupropion hydrochloride + Nicotine Replacement Therapy PatchPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00143325	Phase 3	Completed	Jan 1, 2005	Jun 1, 2006	Smoking Cessation
NCT00143299	Phase 3	Completed	Oct 1, 2003	Mar 1, 2005	Smoking Cessation
NCT00143364	Phase 3	Completed	Jun 1, 2003	Mar 1, 2005	Smoking Cessation
NCT00141206	Phase 3	Completed	May 1, 2003	Apr 1, 2005	Smoking Cessation
NCT00143286	Phase 3	Completed	Apr 1, 2003	Mar 1, 2005	Smoking Cessation

Competing Products

20 competing products in Smoking Cessation

See all competitors

Product	Company	Stage	Hype Score
Brenipatide + Placebo	Eli Lilly	Phase 2	42
Nicotine + Nicotine + Nicotine	Johnson & Johnson	Phase 2	35
Nicotine replacement therapy + Nicotine replacement therapy	Johnson & Johnson	Phase 2	35
Nicotine Patch + Placebo Patch	Johnson & Johnson	Phase 1	29
Nicotine Patch + Placebo Patch + SLS Comparator Patch	Johnson & Johnson	Phase 1	29
Nicotine + Placebo	Johnson & Johnson	Pre-clinical	26
Nicotine Patch + Nicotine Patch Comparator + Placebo Patch	Johnson & Johnson	Phase 1	29
Nicotine Patch + Placebo Patch + No Patch Control	Johnson & Johnson	Phase 1	29
Nicotine gum + Placebo gum + Nicotine inhaler + Placebo inhaler	Johnson & Johnson	Phase 3	40
Nicotine patch, nicotine inhaler, bupropion + Nicotine patch	Johnson & Johnson	Approved	43
AZD4041 + Placebo	AstraZeneca	Phase 1	29
taranabant	Merck	Phase 2	35
Nicotine replacement therapy	Novartis	Pre-clinical	22
AFQ065	Novartis	Phase 1	29
Liraglutide + Placebo	Novo Nordisk	Phase 2	35
Varenicline	Pfizer	Phase 2	35
placebo + Varenicline Tartarate	Pfizer	Phase 3	40
varenicline + placebo	Pfizer	Approved	39
placebo + varenicline	Pfizer	Approved	43
Varenicline + Bupropion	Pfizer	Phase 3	40